About Champions Oncology Inc
- Industry: Life Sciences Tools & Services
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://championsoncology.com
Frequently Asked Questions
What is the 52-week range for CSBR?
The 52-week high is $8.3099 and the 52-week low is $4.59.
What is the P/E ratio for CSBR?
The P/E ratio data is currently unavailable.
What is the dividend yield for CSBR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -27.12%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1.82%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 21.01.
Analyst Recommendation Trends
Wall Street analyst consensus for CSBR over the last few months:
Latest CSBR News
Capitalize on the Global PDX Models Shift: Benchmark Charles River, Crown Bioscience, Champions Oncology, The Jackson Laboratory and Oncodesign to Secure Precision Oncology ROI
PDX adoption is rising as pharma seeks predictive oncology models for precision medicine, biomarker discovery and drug screening, supported by sequencing advances and research partnerships.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Patient Derived Xenograft / PDX Models - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Patient Derived Xenograft / PDX Models was valued at US$467.5 Million in 2024 and is projected to reach US$1 Billion b
Full Transcript: Champions Oncology Q4 2026 Earnings Call
Champions Oncology (NASDAQ:CSBR) reported fourth-quarter financial results on Monday. The transcript from the company's fourth-quarter earnings call has been provided below. This transcript is brought to you by
CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth
Champions Oncology's first-quarter fiscal 2027 results record revenue and margin growth, stronger adjusted earnings and surging data-license revenues.
Champions Oncology Inc (CSBR) (Q1 2027) Earnings Call Highlights: Data Licensing Surge and ...
Champions Oncology Inc (CSBR) posted 9% revenue growth, 50% gross margin, and record data licensing revenue in Q1 fiscal 2027.
Champions Oncology (CSBR) Q1 2027 Earnings Call Transcript
Data licensing revenue surged past full-year fiscal 2026 totals in single quarter.
Champions Oncology, Inc. Q1 2027 Earnings Call Summary
Moby summary of Champions Oncology, Inc.'s Q1 2027 earnings call
Champions Oncology Q1 Earnings Call Highlights
Champions Oncology (NASDAQ:CSBR) reported first-quarter fiscal 2027 revenue growth, improved margins and its fifth consecutive quarter of positive adjusted EBITDA, as both its translational oncology services and data licensing businesses contributed to results. Revenue for the quarter totaled $15.2
Champions Oncology (NASDAQ:CSBR) Shares Jump as Q1 Margins Expand and Adjusted EBITDA Turns Higher
Champions Oncology Q1 revenue hits $15.2M as margins and adjusted EBITDA jump, sending CSBR shares up 13% after hours.
Champions Oncology Reports Revenue of $15.2 Million
Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000HACKENSACK, NJ / ACCESS Newswire / September 10, 2026 / (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026.First Quarter and Recent Highlights: * Revenue of $15.
Champions Oncology Q1 Adj. EPS $0.05 Up From $0.01 YoY, Sales $15.232M Up From $13.995M YoY
Champions Oncology (NASDAQ:CSBR) reported quarterly earnings of $0.05 per share. This is a 400 percent increase over earnings of $0.01 per share from the same period last year. The company reported $15.232 million in
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2025-11-05 | Breitfeld Philip P. | +13,790 | $6.8 | $93,772 |
| 2025-11-05 | Mendelson Daniel Newman | +13,790 | $6.8 | $93,772 |
| 2025-11-05 | SIDRANSKY DAVID | +21,216 | $6.8 | $144,269 |
| 2025-11-05 | ACKERMAN JOEL | +21,216 | $6.8 | $144,269 |
| 2025-11-05 | TOBIN SCOTT R | +25,460 | $6.8 | $173,128 |
| 2025-10-30 | ACKERMAN JOEL | -94,405 | $2.1 | $198,251 |
| 2025-10-30 | ACKERMAN JOEL | +94,405 | $2.1 | $198,251 |